P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2016.08.115
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

An Update on the Safety of Nivolumab for the Treatment of Advanced Melanoma

Expert Opinion on Drug Safety
MedicinePharmacology
2020English

P057 Pembrolizumab + Chemo vs Chemo Alone as First Line Treatment in PD-L1 Positive Advanced NSCLC: A Meta-Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-63 Baseline Biomarkers for Outcome of Advanced NSCLC Patients Receiving Anti-Pd1/Pd-L1 Treatment—Data From a Chinese Population

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1–Selected Patients With NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PD-L1 Expression in Advanced NSCLC: Insights Into Risk Stratification and Treatment Selection From a Systematic Literature Review

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2017English

P1.01-14 Immunotherapy (I) for Advanced, Pre-Treated, Non-Squamous NSCLC (APNS-NSCLC). Preliminary Data of a Pooled Analysis

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

45. A Retrospective Assessment of PD-L1 Expression Rates in NSCLC

Pathology
Forensic MedicinePathology
2020English

The Efficacy and Safety of Anti-Pd-1/Pd-L1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First-Line Treatment for Advanced Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy